Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188877 | 0.85 | CYP1A2 (0.60) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL6023616 | 0.82 | LMNA (0.52) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL6024050 | 0.82 | SMN1; SMN2 (0.69) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL26664855 | 0.81 | HPGD (0.51) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL11279116 | 0.77 | CYP1A2 (0.72) | LMNACYP1A2CYP2C19HPGDALDH1A1 | |
| SCHEMBL26701843 | 0.76 | CYP1A2 (0.58) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL11652842 | 0.76 | HPGD (0.72) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL8545504 | 0.75 | HPGD (0.56) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL9672598 | 0.74 | POLB (0.67) | LMNAKDM4ECYP1A2CYP2C19HPGD | |
| SCHEMBL2010227 | 0.74 | CYP1A2 (0.52) | LMNAKDM4ECYP1A2CYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250289787-A1 | HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-09-18 | — | — | US | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119095827-A | Herbicidal 2-oxo-nicotinic acid derivatives | 先正达农作物保护股份公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2023208710-A1 | HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023208710-A1 | HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289787-A1 | HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES | DDT, NQO2, NAPRT | LMNA 3324/4885KDM4E 2609/4885CYP1A2 118/4885 |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | LMNA 1304/4885KDM4E 4442/4885CYP1A2 1660/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | LMNA 1441/4885KDM4E 4567/4885CYP1A2 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.